Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human EPH Receptor A2 Antibodies:
anti-Rat (Rattus) EPH Receptor A2 Antibodies:
anti-Mouse (Murine) EPH Receptor A2 Antibodies:
Go to our pre-filtered search.
Human Polyclonal EPH Receptor A2 Primary Antibody for CyTOF, FACS - ABIN4899913
Gopal, Bohonowych, Lema-Tome, Liu, Garrett-Mayer, Wang, Isaacs: A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion. in PLoS ONE 2011
Show all 4 Pubmed References
Human Monoclonal EPH Receptor A2 Primary Antibody for CyTOF, FACS - ABIN4899912
Liao-Chan, Daine-Matsuoka, Heald, Wong, Lin, Cai, Lai, DAlessio, Theunissen: Quantitative assessment of antibody internalization with novel monoclonal antibodies against Alexa fluorophores. in PLoS ONE 2015
Show all 4 Pubmed References
Mouse (Murine) Monoclonal EPH Receptor A2 Primary Antibody for CyTOF, FACS - ABIN4899679
De Robertis, Loiacono, Fusilli, Poeta, Mazza, Sanchez, Marchionni, Signori, Lamorte, Vescovi, Garcia-Foncillas, Fazio: Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer. in Clinical cancer research : an official journal of the American Association for Cancer Research 2016
Show all 3 Pubmed References
Human Monoclonal EPH Receptor A2 Primary Antibody for IHC, ELISA - ABIN1724651
Landen, Kinch, Sood: EphA2 as a target for ovarian cancer therapy. in Expert opinion on therapeutic targets 2005
Show all 2 Pubmed References
Human Polyclonal EPH Receptor A2 Primary Antibody for IF (p), IHC (p) - ABIN669201
Wu, Fu, Zhou, Gong, Liu, Qiao, Li: HIF-1? and HIF-2?: siblings in promoting angiogenesis of residual hepatocellular carcinoma after high-intensity focused ultrasound ablation. in PLoS ONE 2014
Human Monoclonal EPH Receptor A2 Primary Antibody for IHC, ELISA - ABIN966072
Abraham, Knapp, Cheng, Snyder, Mittal, Bangari, Kinch, Wu, Dhariwal, Mohammed: Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. in Clinical cancer research : an official journal of the American Association for Cancer Research 2006
Show all 2 Pubmed References
Human Monoclonal EPH Receptor A2 Primary Antibody for FACS - ABIN4896889
Udyavar, Wooten, Hoeksema, Bansal, Califano, Estrada, Schnell, Irish, Massion, Quaranta: Novel Hybrid Phenotype Revealed in Small Cell Lung Cancer by a Transcription Factor Network Model That Can Explain Tumor Heterogeneity. in Cancer research 2017
Human Monoclonal EPH Receptor A2 Primary Antibody for FACS - ABIN4896891
Haas, Sciuto, Brunetto, Valvo, Signore, Fiori, di Martino, Giannetti, Morgante, Boe, Patrizii, Warnken, Schnölzer, Ciolfi, Di Stefano, Biffoni, Ricci-Vitiani, Pallini, De Maria: Integrin α7 Is a Functional Marker and Potential Therapeutic Target in Glioblastoma. in Cell stem cell 2017
findings suggested inhibition of HDACs-EphA2 signaling axis with WW437 alone or in combination with other agents may be a promising therapeutic strategy for advanced breast cancer.
High EPHA2 expression is associated with epithelial-mesenchymal transition in gastric cancer.
Ligand-independent activation of EphA2 was triggered by VEGF (show VEGFA Antibodies) released from CAF (show KAT2B Antibodies)-CM.
EphA2-mediates glutaminolysis through YAP (show YAP1 Antibodies)/TAZ (show TAZ Antibodies) activation in HER2 (show ERBB2 Antibodies)-positive breast cancer and may serve as potential therapeutic targets in patients.
Data indicate a promising role for EPH receptor A2 (EPHA2) as a target in antibody treatments for melanoma.
These observations demonstrate that EphA2 affects the sensitivity to oxaliplatin by inducing EMT (show ITK Antibodies) in oxaliplatin-resistant gastric cancer cells.
High erythropoietin (show EPO Antibodies)-producing hepatocellular carcinoma receptor A (EphA) 1 (show EPHA1 Antibodies), 2, and 4 expression levels were significantly related to recurrence.
Data show that Ephrin B3 (show EFNB3 Antibodies) was concomitantly expressed with EphA2 and Ephrin A1 (show EFNA1 Antibodies) with higher Ephrin B3 (show EFNB3 Antibodies) levels found in non-squamous than in squamous tumors.
These results suggest that EphA2/Efna1/Egfr genes, linked to a possible control by miR-200a and miR-26b, could be proposed as novel CRC prognostic biomarkers. Moreover, EphA2 could be linked to a mechanism of resistance to cetuximab alternative to KRAS mutations.
the dimer structures of human EphA2 receptor depend on the lipid environment, which we show is linked to the location of the structural motifs in the dimer interface, thereby establishing that both sequence and membrane composition modulate the complete energy landscape of membrane-bound proteins.
The present study successfully assessed the expression pattern of miR26b in the pituitary tissue of Yanbian cattle, and also confirmed that EphA2 was a target gene of miR26b in Yanbian cattle in vitro.
Collectively, these data suggest that ATRA attenuates bleomycin-induced pulmonary fibrosis by regulating EphA2-EphrinA1 and PI3K-Akt (show AKT1 Antibodies) signaling.
Lipopolysaccharide exposure significantly up-regulated EphA2 and EphrinA1 expression.
modulation of EphA2 signaling might contribute to effective transplantation of tissue-specific resident macrophages and/or monocytes
Our data suggest that EphA2 is closely related to the formation of osteoblasts and resorption of osteoclast and is likely to play an role in bone resorption induced in chronic periodontitis
We examined the roles of ephrin-A2 (show EFNA2 Antibodies) and ephrin-A5 (show EFNA5 Antibodies) signaling in contralateral targeting and topographic ordering in the ventral cochlear nucleus
EphA2 acts as a KRas cooperative tumor suppressor
Data shows that modulation of angiostatic factor Slit2 (show SLIT2 Antibodies) by EphA2 receptor regulates endothelial responses to VEGF (show VEGFA Antibodies)-mediated angiogenesis and tumor neovascularization.
Sporozoites productively infected hepatocytes with high EphA2 expression, and the deletion of EphA2 protected mice from liver infection.
EphA2-mutant mice are more prone to hyperglycemia-induced increased injury and decreased survival.
This gene belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. EPH and EPH-related receptors have been implicated in mediating developmental events, particularly in the nervous system. Receptors in the EPH subfamily typically have a single kinase domain and an extracellular region containing a Cys-rich domain and 2 fibronectin type III repeats. The ephrin receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. This gene encodes a protein that binds ephrin-A ligands. Mutations in this gene are the cause of certain genetically-related cataract disorders.
ephrin type-A receptor 2
, epithelial cell receptor protein tyrosine kinase
, soluble EPHA2 variant 1
, tyrosine-protein kinase receptor ECK
, ephrin receptor EphA2
, epoxide hydrolase
, EPH receptor A2
, epithelial cell kinase
, tyrosine-protein kinase receptor MPK-5
, tyrosine-protein kinase receptor SEK-2
, protein tyrosine kinase EphA2
, eph-like receptor tyrosine kinase 6
, EPH receptor A2 L homeolog
, ephrin receptor EphA2 (tyrosine kinase family)